Stephen A Jannetti, Giuseppe Carlucci, Brandon Carney, Susanne Kossatz, Larissa Shenker, Lukas M Carter, Beatriz Salinas, Christian Brand, Ahmad Sadique, Patrick L Donabedian, Kristen M Cunanan, Mithat Gönen, Vladimir Ponomarev, Brian M Zeglis, Mark M Souweidane, Jason S Lewis, Wolfgang A Weber, John L Humm, Thomas Reiner
The DNA repair enzyme PARP1 is over-expressed in glioblastoma, with overall low expression in healthy brain tissue. Paired with the availability of specific molecularly targeted small molecules for this biomarker, PARP1 is a near-ideal target for novel radiotherapeutics. A successful PARP1-targeted radiotherapeutic would induce DNA damage and apoptosis in cancer cells, while sparing healthy brain tissue. We synthesized a131 I-labeled poly(ADP-ribose) polymerase 1 (PARP1) therapeutic and investigated its pharmacology using in vitro and in vivo methodologies...
March 23, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine